Arizona Tribune - Zomedica Announces Strategic PulseVet(R) Shock Wave Partnership with World Equestrian Center – Ocala

ANN ARBOR, MI / ACCESS Newswire / July 10, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced a strategic sponsorship agreement between its leading brand, the PulseVet shock wave device, and the World Equestrian Center - Ocala (WEC), one of the premier equestrian venues in the world. This partnership designates the PulseVet device as the official shock wave therapy provider at WEC - Ocala, enhancing veterinary care for elite equine athletes and reinforcing Zomedica's commitment to advancing animal health through innovative technologies.

Through this partnership, PulseVet shock wave will receive broad visibility across the WEC Ocala property, including branded signage in competition arenas, digital scoreboard promotions, and features in the WEC Weekly newsletter and World Equestrian Center Magazine. The PulseVet shock wave team will also offer on-site educational resources and promotional materials to support equine veterinarians and caretakers.

"This partnership is a game-changer in bringing world-class therapy to a world-class venue," said Trudy Gage, Vice President of Equine Sales and Client Education at Zomedica. "Our PulseVet systems are trusted by veterinarians and equine professionals across the globe for their ability to accelerate healing and improve performance. We're honored to align with WEC - Ocala and contribute to their commitment to equine excellence."

The PulseVet system is a leading non-invasive shock wave therapy used to treat a wide range of musculoskeletal injuries in horses. Its ability to stimulate healing at the cellular level has made it an essential tool for veterinarians treating performance horses at the highest level.

"Our presence at WEC - Ocala not only highlights the impact of PulseVet shock wave therapy in equine care but also underscores Zomedica's broader commitment to equipping veterinarians with industry-leading technologies," said Courtney Calnan, Senior Product Manager at Zomedica. "This collaboration reflects our dedication to innovation and meaningful partnerships that ultimately improve outcomes for animals and the professionals who care for them."

In addition to enhanced brand exposure and marketing benefits, Zomedica will receive hospitality privileges during WEC events, including discounted lodging, VIP event access, and opportunities to engage directly with the equestrian community.

About World Equestrian Center - Ocala
Named one of TIME's 2024 World's Greatest Places, World Equestrian Center features two premier equestrian and multidisciplinary venues in Ocala, Florida, and Wilmington, Ohio.

These exclusive facilities comprise state-of-the-art arenas, expansive stadiums, versatile outdoor space, sporting fields and well-appointed exposition centers. An abundance of lodging options and luxury accommodations are conveniently located on-site, along with shopping and dining throughout each property.

Dedicated to offering great sport and good fun in a family-friendly environment, World Equestrian Center promises an unparalleled experience for exhibitors, spectators, vendors, sponsors and retailers built on three core values: Quality. Class. Distinction.

About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet^® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi^® Loop line of therapeutic devices and the TRUFORMA^® diagnostic platform, the TRUVIEW^® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $65 million in liquidity as of March 31, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.

Follow Zomedica

• Email Alerts: http://investors.zomedica.com

• LinkedIn: https://www.linkedin.com/company/zomedica

• Facebook: https://m.facebook.com/zomedica

• X (formerly Twitter): https://twitter.com/zomedica

• Instagram: https://www.instagram.com/zomedica_inc

Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes;; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:
Zomedica Investor Relations
[email protected]
1-734-369-2555

SOURCE: Zomedica Corp.

View the original press release on ACCESS Newswire

T.Wright--AT